Stevanato Group S.p.A.

Equities

STVN

IT0005452658

Medical Equipment, Supplies & Distribution

Market Closed - Nyse 04:00:02 2024-03-28 pm EDT 5-day change 1st Jan Change
32.1 USD +0.72% Intraday chart for Stevanato Group S.p.A. +13.39% +17.63%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Stevanato Group Closes $379.7 Million Public Share Offering MT
Stevanato Group Prices Upsized $330 Million Public Share Offering; Shares Rise MT
Sector Update: Health Care Stocks Steady Pre-Bell Friday MT
Stevanato Group Prices Upsized $330 Million Public Share Offering MT
Sector Update: Health Care Stocks Gain Pre-Bell Thursday MT
Stevanato Group Launches Primary, Secondary Offerings; Shares Drop After Hours MT
UBS Raises Stevanato Price Target to $34 From $31, Maintains Neutral Rating MT
Stevanato Group Q4 Adjusted Earnings Declines, Revenue Rises; Shares Fall MT
Sector Update: Health Care Stocks Mixed Pre-Bell Thursday MT
Sector Update: Health Care MT
Transcript : Stevanato Group S.p.A., Q4 2023 Earnings Call, Mar 07, 2024
Stevanato Group Q4 Adjusted Earnings Declines, Revenue Rises MT
Stevanato Group S.p.A. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Stevanato Group S.p.A. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 CI
Stevanato Group S.P.A. Provides Revenue Guidance for the Full Year of 2024 CI
Stevanato Group S.p.A. Launches EZ-fill®? Kit and Laboratory Fill and Finish Service to Support Small Batch Drug Development and Commercialization CI
Transcript : Stevanato Group S.p.A. Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-10-2024 08:15 AM
Stevanato Group Slips Amid Jefferies' Downgrade to Hold MT
Morgan Stanley Adjusts Price Target on Stevanato to $30 From $34, Keeps Equalweight Rating MT
Jefferies Downgrades Stevanato to Hold From Buy, Adjusts Price Target to $29 From $39 MT
How Novo Nordisk makes its weight-loss drug Wegovy RE
Transcript : Stevanato Group S.p.A., Q3 2023 Earnings Call, Oct 31, 2023
Stevanato Group S.p.A. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Stevanato Group S.P.A. Reiterates Revenue Guidance for the Full Year 2023 CI
BofA Securities Raises Price Target on Stevanato to $39 From $35, Maintains Buy Rating MT
Chart Stevanato Group S.p.A.
More charts
Stevanato Group SpA is an Italy-based manufacturer and distributor engaged in two segments: Biopharmaceutical and Diagnostic Solutions and Engineering, including the production and distribution of drug containment solutions, drug delivery systems, and diagnostic solutions in the pharmaceutical industry. The Company delivers products, processes, and services across all stages of drug developments, including pre-clinical, clinical, and commercialization. Its Engineering segment includes the equipment and technologies developed and provided to support the end-to-end pharmaceutical, biotechnology, and diagnostic manufacturing processes. The Company operates locally, in Europe, and globally, including Brazil, China, Mexico, and the United States.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
-
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
32.1 USD
Average target price
34.74 USD
Spread / Average Target
+8.23%
Consensus
  1. Stock
  2. Equities
  3. Stock Stevanato Group S.p.A. - Nyse
  4. News Stevanato Group S.p.A.
  5. Stevanato S p A : Morgan Stanley Adjusts Stevanato Group's Price Target to $28 From $26, Keeps Overweight Rating